Updated October 202670+ pagesPDF

Longevity Report

Funding, valuations and who’s ahead

Cover of NewMarketPitch's Longevity report: funding, valuations and who's ahead, 2026 edition
Is Neko Health, the body-scan startup, really worth $7 billion? Not on sales, mostly on promise. Neko sold ~$16M of body scans in 2025 and lost ~$70M. At ~$7B, it is valued at 430 times its sales. Chart from NewMarketPitch's Longevity report.
Do full-body scans find far more scares than cancers? Yes. In the latest review of 17 studies, 78 of 100 people scanned had a finding and ~15 needed more tests for something that was not cancer. ~1 had a cancer. Chart from NewMarketPitch's Longevity report.
Will dogs get a drug approved to extend life before people do? Very likely. Loyal’s pill for older dogs has 2 of the 3 parts of its FDA file accepted. For people, there is no path yet: the FDA does not treat aging as a disease. Chart from NewMarketPitch's Longevity report.
How many drugs are approved to treat aging itself? None, the FDA does not treat aging as a disease. Yet billions went into the hunt, from Altos Labs’ $3B to $1.65B for aging-drug startups recently. Chart from NewMarketPitch's Longevity report.
How expensive are longevity companies, measured by sales? Very, in private rounds. Neko Health is valued at ~430 times its 2025 sales. The GLP-1 giants, Novo and Lilly, trade at 3.5 and 14 times. Chart from NewMarketPitch's Longevity report.
Do a few longevity startups take most of the money? Yes. Neko, NewLimit and Function took 51% of the $3.75B raised by longevity startups recently. The top ten took 71%. Chart from NewMarketPitch's Longevity report.
Are clinics and supplements selling longevity without proof? Yes. No longevity clinic or supplement has shown in a trial that it adds healthy years. GLP-1s cut deaths, but only in people with heart disease. Chart from NewMarketPitch's Longevity report.
Is the reprogramming lab closest to people worth most? No. Altos, valued highest at ~$6.3B, has not named a drug yet. Life Biosciences, the only one already testing in people, publishes no value. Chart from NewMarketPitch's Longevity report.
Neko or Function: who leads the longevity checkup? Function on people, 500,000+ members, and on sales, ~$100M (an estimate). Neko on money, $960M raised and a ~$7B value. Chart from NewMarketPitch's Longevity report.

70+ pages in the full report

Swipe· 70+ pages in the report

Inside the report

  • Who are the top companies today
  • Who’s ahead, and who’s falling behind
  • What are their valuations
  • Who’s getting funded, and by whom
  • Who’s growing the fastest
  • Which investors are making the biggest bets
  • Which business models are winning
  • What are the biggest unsolved problems
  • What technologies are gaining traction
  • What has changed in the last 12 months
  • Where are the biggest opportunities
  • Who are the likely future winners
$99$79one-time payment
Get the report

Verified data with sourcesUpdated in October 2026